AMDL Terminates Wainwright Agreement
July 26 2004 - 8:00AM
PR Newswire (US)
AMDL Terminates Wainwright Agreement TUSTIN, Calif., July 26
/PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and
marketer of tests for the early detection of cancer and other
serious diseases, today announced that it has terminated its best
efforts funding agreement with H. C. Wainwright & Co., Inc.,
which had been detailed in the Company's most recent 10-QSB filing
with the U.S. Securities & Exchange Commission. No funds were
raised by Wainwright in the proposed offering. The Company said it
may continue to investigate financing alternatives and
opportunities such as joint ventures or distribution financing.
There are no other funding agreements in place at this time. AMDL
believes it has adequate financial resources to pursue its current
business plan. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in
Tustin, California, is a theranostics company, involved in the
detection and treatment of the same disease, cancer. AMDL is the
inventor, developer and worldwide marketer through exclusive
distribution agreements of the DR-70(R) non-invasive cancer blood
test, which has demonstrated its ability to detect the presence in
humans of up to 13 cancers 84 percent of the time overall. In a
study published in the Journal of Immunoassay (1998, vol. 19, pp
63-72) DR-70(R) was shown to detect at least 13 different types of
cancer (lung, breast, stomach, liver, colon, rectal, ovarian,
esophageal, cervical, trophoblastic, thyroid, malignant lymphoma,
pancreatic) although the sample size for 9 of the cancers was not
statistically significant. Clinical trials of DR-70(R) have been
conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R)
can detect many kinds of cancer using a single tube of blood,
eliminating the need for costly, multiple tests. AMDL also owns a
combination immunogene therapy technology that is a possible
treatment for those already diagnosed with cancer and could
eventually be used as a vaccine to protect patients known to be at
risk because of a family history for certain types of cancer. The
combination therapy both builds the body's immune system and
destroys cancer cells. More information about AMDL and its
additional products can be obtained at
http://www.amdlcorporate.com/. Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdlcorporate.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024